1. Introduction {#sec1-marinedrugs-16-00093}
===============

Previous chemical investigations on the octocorals of the genus *Lobophytum* have led to the isolation of structurally unique steroids \[[@B1-marinedrugs-16-00093],[@B2-marinedrugs-16-00093],[@B3-marinedrugs-16-00093],[@B4-marinedrugs-16-00093],[@B5-marinedrugs-16-00093],[@B6-marinedrugs-16-00093]\], some of which have been shown to exhibit cytotoxic \[[@B2-marinedrugs-16-00093],[@B3-marinedrugs-16-00093],[@B5-marinedrugs-16-00093],[@B6-marinedrugs-16-00093]\] and anti-inflammatory \[[@B2-marinedrugs-16-00093],[@B5-marinedrugs-16-00093]\] activities. For the purpose of searching for bioactive compounds, we have previously investigated the chemical constituents of soft corals of the genus *Lobophytum* growing in Taiwanese waters, which resulted in the discovery of a series of bioactive natural products \[[@B6-marinedrugs-16-00093],[@B7-marinedrugs-16-00093],[@B8-marinedrugs-16-00093],[@B9-marinedrugs-16-00093],[@B10-marinedrugs-16-00093],[@B11-marinedrugs-16-00093]\]. Previous investigations also have shown that the soft coral *Lobophytum michaelae* could produce bioactive cembranolides with cytotoxicity towards cancer cell lines \[[@B12-marinedrugs-16-00093],[@B13-marinedrugs-16-00093],[@B14-marinedrugs-16-00093]\]. With the aim of discovering more bioactive marine natural products for new drug development in the future, we again investigated the chemical constituents of a Formosan soft coral *L. michaelae*. From this study, we have isolated three new polyoxygenated steroids, michosterols A--C (**1**--**3**), together with four known compounds: brassicasterol (**4**) \[[@B15-marinedrugs-16-00093]\], 24*S*-methylcholesterol (**5**) \[[@B16-marinedrugs-16-00093]\], 23-demethylgorgosterol (23-demethylgorgost-5-en-3β-ol) (**6**) \[[@B17-marinedrugs-16-00093],[@B18-marinedrugs-16-00093],[@B19-marinedrugs-16-00093]\] and gorgosterol (**7**) \[[@B20-marinedrugs-16-00093]\]. Extensive spectroscopic analyses, including mass spectrometry, 1D and 2D NMR spectroscopy ([Supplementary Materials, Figures S1--S26](#app1-marinedrugs-16-00093){ref-type="app"}), and comparison of spectroscopic data of the new compounds with those of the previously reported structurally-related compounds have allowed us to establish the structures of **1**--**3**. Compound **1** possesses a double bond between C-16 and C-17 and an unusual side-chain with a hydroperoxyl group at C-20, whereas **2** has this group at C-16 and an uncommon olefinic structure at C-17 and C-20. The in vitro cytotoxicity of **1**--**3** against three cancer cell lines, adenocarcinomic human alveolar basal epithelial (A549), human colorectal adenocarcinoma (DLD-1) and human prostatic carcinoma (LNCap), was evaluated. The abilities of compounds **1**--**3** to inhibit superoxide anion generation and elastase release in *N*-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLP/CB)-stimulated human neutrophils was also assayed.

2. Results and Discussion {#sec2-marinedrugs-16-00093}
=========================

The frozen bodies of *L. michaelae* were sliced and exhaustively extracted with ethyl acetate (EtOAc). The EtOAc extract was separated by repeated gravity column chromatography and high-performance liquid chromatography (HPLC) to afford three new and four known triterpenoids steroids **1**--**7** ([Figure 1](#marinedrugs-16-00093-f001){ref-type="fig"}).

The molecular formula of **1**, an amorphous solid, was determined as C~31~H~52~O~7~ based on the \[M + Na\]^+^ ion peak obtained by high-resolution electron spray ionisation mass spectrometry (HRESIMS), implying six degrees of unsaturation. The ^13^C NMR spectrum showed 31 carbon signals, including an ester carbonyl (δ~C~ 171.9, C), a double bond (δ~C~ 157.6, C and 127.0, CH), two oxymethines (δ~C~ 71.8 and 67.7, each CH) and three oxygenated *sp*^3^ quaternary carbons (δ~C~ 87.2, 85.6, and 78.1) ([Table 1](#marinedrugs-16-00093-t001){ref-type="table"}). The ^1^H NMR spectrum in conjunction with the heteronuclear single quantum coherence (HSQC) spectrum revealed the presence of eight methyl groups (δ~H~ 2.03 (3H, s), 1.50 (3H, s), 1.41 (3H, s), 1.31 (3H, s), 0.96 (6H, s), 0.93 (3H, d, *J* = 6.8 Hz) and 0.88 (3H, d, *J* = 7.2 Hz)), an olefinic methine proton (δ~H~ 5.70 (1H, d, *J* = 2.0 Hz)) and a hydroperoxy group signal at δ~H~ 8.06 (br s). Thus, the remaining four unsaturations of **1** corresponded to a tetracyclic skeleton. In the correlation spectroscopy (COSY) spectrum, it was possible to identify three different structural units extending from C-1 to C-4; C-6 to both C-12 and C-16 through C-8; and C-22 to both C-28 and C-29 through C-23 ([Figure 2](#marinedrugs-16-00093-f002){ref-type="fig"}). From the heteronuclear multiple-bond correlation (HMBC) spectrum, the correlations of H~3~-19 to C-1, C-5, C-9 and C-10, H~3~-18 to C-12, C-13, C-14 and C-17, H-6 to C-4 and C-5, H-16 to C-20, H~3~-21 to C-17, C-20 and C-22, both H~3~-26 and H~3~-27 to C-24 and H~3~-28 to C-25 permitted the establishment of the carbon skeleton of a 23,24-dimethycholestane ([Figure 2](#marinedrugs-16-00093-f002){ref-type="fig"}). The hydroperoxy group positioned at C-20 was confirmed from the HMBC correlation of the hydroperoxy proton δ~H~ 8.06 (br s) to the oxygenated carbon at δ~C~ 85.6; hence, the acetoxy group was positioned at C-25 (δ~C~ 87.2). The planar structure of **1** was thus established unambiguously.

The relative configuration of **1** was deduced by interpretation of the nuclear Overhauser effect (NOE) correlations ([Figure 3](#marinedrugs-16-00093-f003){ref-type="fig"}), analysis of ^3^*J*~H-H~ values and comparison of carbon chemical shifts. As depicted in [Figure 3](#marinedrugs-16-00093-f003){ref-type="fig"}, it was found that the NOE interactions displayed by both H~3~-18 and H~3~-19 with H-8 and H~3~-19 with H-6, while one of the methylene protons at C-7 (δ~H~ 1.85, m), showed NOESY correlations with both of H-6 and H-8. Therefore, assuming the β-orientation of H~3~-19, H-6, H-7 at δ~H~ 1.85, H-8 and H~3~-18 should be positioned on the β-face, while the other H-7 (δ~H~ 1.09, q, *J* = 12.0 Hz) was assigned as H-7α. Moreover, H-14 showed NOESY correlations with H-7α, H-9 and one proton of H~2~-12 (δ~H~ 2.06, m); whereas the latter proton was NOE correlated with H~3~-21. This reflects theα-orientations of H-9, H-14 and H~3~-21 and, consequently, the β-orientation of the hydroperoxy group at C-20 of the side chain. Further, H~3~-21 exhibited NOESY correlation with H-23; and H-23 expressed NOE interaction with H-24 as did H~3~-28 with H~3~-29, respectively, while no NOE interaction was found for H-23 with H~3~-28 and for H-24 with H~3~-29. Thus, the 23*R\**, 24*S\** relative configurations were revealed ([Figure 3](#marinedrugs-16-00093-f003){ref-type="fig"}) and further supported by the comparison of the NOE interactions in **1** with those anticipated in its other three 23,24-rotamers ([Figure 4](#marinedrugs-16-00093-f004){ref-type="fig"}). Finally, the configurations of C-3, C-5 andC-6 were elucidated by comparison of the ^1^H NMR chemical shifts and coupling constants of H-3 and H-6 with those of related steroids ([Table 2](#marinedrugs-16-00093-t002){ref-type="table"}). The δ and *J* values of H-3 (δ~H~ 4.24, s) and H-6 (δ~H~ 3.74--3.81, dd, *J* = 12.0, 4.8 Hz) of known compound 5β-cholestane-3β,5,6α-triol \[[@B21-marinedrugs-16-00093],[@B22-marinedrugs-16-00093]\] were found to be similar to the corresponding H-3 (δ~H~ 4.27, br s) and H-6 (δ~H~ 3.82, dd, *J* = 12.0, 4.8 Hz) of **1** ([Table 2](#marinedrugs-16-00093-t002){ref-type="table"}). Consequently, the relative configuration of **1** was determined unequivocally. Since it has been known for quite a long time that both H~3~-18 and H~3~-19 should be positioned on the β-face for natural steroids, thus the absolute configuration of **1** should be the same as shown in Structure **1**.

Analysis of the ^13^C NMR and HRESIMS spectral data of **2** revealed that it has the same molecular formula as that of **1**. The ^1^H and ^13^C NMR spectra of **2** are similar to those of **1**, and the molecular skeleton of **2** was further established by HMBC correlations from H~3~-21 to C-17 (δ~C~ 143.6, C), C-20 (δ~C~ 132.8, C) and C-22 (δ~C~ 41.2, CH~2~); H-16 (δ~H~ 4.96, dd, *J* = 7.5, 7.5 Hz) to C-13 (δ~C~ 44.1, C) and C-20; and the COSY correlation between H~2~-15 and H-16 ([Figure 2](#marinedrugs-16-00093-f002){ref-type="fig"}). The above results showed that an olefinic proton signal (δ~H~ 5.70, d, *J* = 2.0 Hz) in **1** was replaced by an oxymethine proton (δ~H~ 4.96, dd, *J* = 7.5, 7.5 Hz), which also showed correlation with the signal of C-16 (δ~C~ 86.1) in the HSQC spectrum of **2**. Further, a proton signal appearing at δ~H~ 8.91 (br s) was found not to be correlated with any carbon signal in the HSQC spectrum. Thus, this should be the signal of a hydroperoxy group substituted at C-16, as confirmed by the downfield shift of this carbon in **2** in comparison with the chemical shifts of the corresponding carbons of two 16-hydroxy analogues, δ~C~ 72.3 for faccisteroid B \[[@B23-marinedrugs-16-00093]\] and 71.8 for hippuristerone L \[[@B24-marinedrugs-16-00093]\]. The comparison of the ^1^H NMR chemical shifts and the analysis of NOESY correlations of **2** revealed the same configurations at C-3, C-5, C-6, C-8, C-9, C-10, C-13, C-14, C-23 and C-24 as those of **1**. Further, NOESY correlations from H~3~-18 to H-8, H-15β (δ~H~ 1.69, m) and H-22β (δ~H~ 1.76 m) were observed, while H-15α (δ~H~ 2.08 m) was correlated with H-14 and H-16 and H-16 with H~3~-21, suggesting a β-orientation of hydroperoxy group at C-16 and the *E* geometry of Δ^17(20)^ in **2**. On the basis of the above findings and the careful analysis of NOESY correlations ([Figure 5](#marinedrugs-16-00093-f005){ref-type="fig"}), the structure of **2** was determined as illustrated in [Figure 1](#marinedrugs-16-00093-f001){ref-type="fig"}.

Michosterol C (**3**) was isolated as a white powder and has a molecular formula of C~30~H~52~O~5~ by the analysis of HRESIMS. The IR spectrum of **3** also revealed the presence of hydroxy (3416 cm^−1^) and ester carbonyl (1718 cm^−1^) groups. Comparison of the ^1^H and ^13^C NMR data ([Table 1](#marinedrugs-16-00093-t001){ref-type="table"}) of compounds **2** and **3** pointed out that the A--C rings of **3** were similar to those of **2**, with the exception of signals assigned to C-6, where the hydroxymethine (δ~H~ 3.80, dd, *J* = 12.0, 5.0 Hz; δ~C~ 71.7) in **2** was replaced by an acetoxymethine (δ~H~ 4.97, dd, *J* = 12.0, 4.8 Hz; δ~C~ 75.8) in **3**. The acetoxy group substitution at C-6 was determined by the HMBC correlations of H-6 (δ~H~ 4.97) with C-4 (δ~C~ 31.1, CH~2~), C-5 (δ~C~ 77.4, C) and an acetoxy carbonyl carbon (δ~C~ 171.9, C), and further confirmed by the COSY spectrum ([Figure 2](#marinedrugs-16-00093-f002){ref-type="fig"}). Furthermore, the signal of a hydroperoxy-bearing methine group at C-16 (δ~H~ 4.96, dd, *J* = 7.5, 7.5 Hz; δ~C~ 86.1) in **2** was replaced by signals of a methylene group (H~2~-16:δ~H~ 1.28 m and 1.84 m; δ~C~ 28.0). Comparison of the NMR data of **3**, measured in CD~3~OD (see the Experimental Section) with those of (24S)-ergostane-6-acetate-3β,5α,6β,25-tetraol \[[@B21-marinedrugs-16-00093]\] indicated that the planar structure and the configurations of the side chain of both compounds are the same. Furthermore, the configurations of C-3, C-5 and C-6 were elucidated by comparison of the ^1^H NMR coupling constants with the related steroids ([Table 1](#marinedrugs-16-00093-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00093-t002){ref-type="table"}). The *J* values of H-3 (δ~H~ 4.11, br s) and H-6 (δ~H~ 4.97, dd, *J* = 12.0, 4.8 Hz) of compound **3** were identical to the corresponding H-3 (δ~H~ 4.27, br s) and H-6 (δ~H~ 3.82, dd, *J* = 12.0, 4.8 Hz) of **1**. In addition, NOESY correlations of H~3~-19 with both H-6 and H-8, H-8 with H-7β (δ~H~ 1.81, m), H-7α (δ~H~ 1.07, m) with H-4α (δ~H~ 1.92, m) and H-9 and H-4α with H-3 confirmed the α-orientations of the H-3 and 6-OAc group and the β-orientation of the 5-OH group ([Figure 5](#marinedrugs-16-00093-f005){ref-type="fig"}). Thus, the structure of **3** was established as shown in [Figure 1](#marinedrugs-16-00093-f001){ref-type="fig"}.

The cytotoxicity of the isolates **1**--**3** against A549, DLD-1 and LNCap cancer cells was assayed. The results showed that only compound **1** exhibited a moderate cytotoxicity effect against the A549 cell line with an IC~50~ value of 14.9 ± 5.7 μg/mL. The other compounds were found not to be cytotoxic against the above cancer cell lines (IC~50'~s \> 20 μg/mL).

The anti-inflammatory activities of the new compounds **1**--**3** on pro-inflammatory responses were evaluated by measuring their ability to suppress fMLP/CB-induced superoxide anion (O~2~^−•^) generation and elastase release in human neutrophils. From the results ([Table 3](#marinedrugs-16-00093-t003){ref-type="table"}), compound **1** showed significant inhibitory effects against superoxide anion generation and elastase release in fMLP/CB-stimulated cells at the 10 μM concentration tested, with the IC~50~ values being 7.1 ± 0.3 μM and 4.5 ± 0.9 μM, respectively. Further, compound **3** exhibited stronger inhibitory activities against elastase release, with the IC~50~ values of 0.9 ± 0.1 μM.

3. Experimental Section {#sec3-marinedrugs-16-00093}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-16-00093}
------------------------------------

The specific optical rotation values and IR spectral absorptions were recorded on a JASCO P-1020 digital polarimeter (JASCO Corporation, Tokyo, Japan) and a JASCO J-815 spectrophotometer (JASCO Corporation), respectively. A Varian 400MR FT-NMR or Varian Unity INOVA-500 FT-NMR (Varian Inc., Palo Alto, CA, USA) was applied to record the ^1^H and ^13^C NMR spectra with the chemical shifts shown as ppm referenced to the solvent residue of CDCl~3~ (δ~H~ 7.26 ppm and δ~C~ 77.0 ppm) and CD~3~OD (δ~H~ 3.31 ppm and δ~C~ 49.0 ppm), respectively. A Bruker APEX II mass spectrometer equipped with an ESI ionization source (Bruker, Bremen, Germany) was used for acquiring high-resolution mass data. The HPLC system used in this study was composed of a Hitachi L-2455 instrument (Hitachi Ltd., Tokyo, Japan) equipped with a reversed-phase (RP-18) column (ODS-3, 5 μm, 250 × 20 mm, Sciences Inc., Tokyo, Japan).

3.2. Animal Material {#sec3dot2-marinedrugs-16-00093}
--------------------

The collection of the soft coral *Lobophytum michaelae* Tixier-Durivault (1956) was performed off the coast of Jihui Fishing Port, Taitung County, Taiwan, in March 2013. The organism was stored in a freezer at −20 °C until extraction. Prof. C.-F. Dai performed the species identification. A voucher specimen (JiH-201314) of this soft coral has been deposited at National Sun Yat-sen University.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-16-00093}
-----------------------------

The frozen bodies of *L. michaelae* (3.2 kg, wet wt) were sliced and exhaustively extracted with EtOAc (3 × 4 L). The EtOAc extract (5.95 g) was chromatographed over silica gel by column chromatography and eluting with EtOAc in *n*-hexane (0--100%, stepwise), followed by acetone in EtOAc (50--100%, stepwise) to yield 22 fractions. Fraction 9 was eluted with acetone/*n*-hexane (1:6) on silica gel to give twelve subfractions (SFr.9-1--SFr.9-12), and SFr.9-3 was separated on RP-18 gel, using MeOH/H~2~O (7:1) to give ten subfractions (SFr.9-3-1--SFr.9-3-10); SFr.9-3-2 was subjected to PR-HPLC with CH~3~CN/MeOH (1:10) to obtain compounds **4** (1.9 mg), **5** (3.6 mg), **6** (2.9 mg) and **7** (3.4 mg). Fraction 14, eluted with *n*-hexane/EtOAc (1:4), also was rechromatographed over a Sephadex LH-20 column, using acetone as the mobile phase. In turn, SFr. 14-2 was separated on silica gel, using acetone/*n*-hexane (1:4) to give two subfractions SFr. 14-2-1--SFr.14-2-2. SFr.14-2-2 was isolated on RP-HPLC using MeOH/H~2~O (10:1) to give **3** (32.3 mg). SFr.14-4 was further purified by reversed phase HPLC using methanol/H~2~O (4: 1) to obtain **1** (5.6 mg) and **2** (1.6 mg).

Michosterol A (**1**): amorphous solid; \[α\]${}_{D}^{25}$ −5 (*c* 1.25, CHCl~3~); IR (neat) *v*~max~ 3393, 2972, 2938, 1712, 1453, 1371, 1270, 1153, 1051 and 757 cm^--1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 1](#marinedrugs-16-00093-t001){ref-type="table"}; ESIMS *m*/*z* 559 \[M + Na\]^+^; HRESIMS *m*/*z* 559.3601 \[M + Na\]^+^ (calcd. for C~31~H~52~O~7~Na, 559.3605).

Michosterol B (**2**): amorphous solid; \[α\]${}_{D}^{25}$ −51 (*c* 0.25, CHCl~3~); IR (neat) *v*~max~ 3418, 2933, 1713, 1455, 1375, 1259, 1053 and 756 cm^--1^; ^13^C and ^1^H NMR data (500 MHz; CDCl~3~), see [Table 1](#marinedrugs-16-00093-t001){ref-type="table"}; ESIMS *m*/*z* 559 \[M + Na\]^+^; HRESIMS *m*/*z* 559.3603 \[M + Na\]^+^ (calcd. for C~31~H~52~O~7~Na, 559.3605).

Michosterol C (**3**): white powder; \[α\]${}_{D}^{25}$ +34 (*c* 0.91, CHCl~3~); IR (neat) *v*~max~ 3416, 2942, 2870, 1718, 1454, 1375, 1260, 1049 and 756 cm^--1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 1](#marinedrugs-16-00093-t001){ref-type="table"}; ^1^H NMR (CD~3~OD, 400 MHz): δ~H~ 4.94 (1H, dd, *J* = 12.0, 5.2 Hz, H-6), δ~H~ 4.14 (1H, br s, H-3), δ~H~ 2.07 (3H, s, H-6-OAc), δ~H~ 2.04 (1H, m, H-12a), δ~H~ 1.97 (2H, m, H~2~-4), δ~H~ 1.89 (1H, m, H-16a), δ~H~ 1.84 (1H, m, H-7a), δ~H~ 1.83 (1H, m, H-1a), δ~H~ 1.76 (1H, m, H-23a), δ~H~ 1.65 (1H, m, H-2a), δ~H~ 1.59 (2H, m, H-2b and H-8), δ~H~ 1.58 (1H, m, H-15a), δ~H~ 1.56 (1H, m, H-22a), δ~H~ 1.48 (1H, m, H-11a), δ~H~ 1.40 (1H, m, H-20), δ~H~ 1.36 (2H, m, H-1b and H-11b), δ~H~ 1.32 (1H, s, H-24), δ~H~ 1.31 (1H, m, H-16), δ~H~ 1.20 (1H, m, H-12b), δ~H~ 1.19 (1H, m, H-17), δ~H~ 1.14 (1H, m, H-14), δ~H~ 1.13 (3H, s, H~3~-27), δ~H~ 1.12 (1H, m, H-15), δ~H~ 1.11 (3H, s, H~3~-26), δ~H~ 1.07 (1H, m, H-7b), δ~H~ 0.97 (3H, s, H~3~-19), δ~H~ 0.96 (3H, d, *J* = 5.2 Hz, H~3~-21), δ~H~ 0.95 (1H, m, H-22b), δ~H~ 0.89 (3H, d, *J* = 6.8 Hz, H~3~-28), δ~H~ 0.78 (1H, m, H-23), δ~H~ 0.71 (3H, s, H~3~-18); ^13^C NMR (CD~3~OD, 100 MHz): 173.0 (C, C-6-OAc), 78.1 (C, C-5), 76.3 (CH, C-6), 74.4 (C, C-25), 68.2 (CH, C-3), 57.7 (CH, C-14), 57.6 (CH, C-17), 46.6 (CH, C-24), 44.4 (CH, C-9), 44.1 (C, C-13), 43.2 (C, C-10), 41.4 (CH~2~, C-12), 38.0 (CH, C-20), 36.5 (CH~2~, C-22), 35.3 (CH, C-8), 34.8 (CH~2~, C-7), 32.1 (CH~2~, C-4), 29.5 (CH~2~, C-16), 29.4 (CH~2~, C-23), 28.5 (CH~2~, C-2), 27.4 (CH~3~, C-27), 26.7 (CH~2~, C-1), 26.0 (CH~3~, C-26), 25.5 (CH~2~, C-15), 23.0 (CH~2~, C-11), 21.6 (CH~3~, C-6-OAc), 19.8 (CH~3~, C-21), 17.9 (CH~3~, C-19), 15.5 (CH~3~, C-28), 12.8 (CH~3~, C-18); ESIMS *m*/*z* 515 \[M + Na\]^+^; HRESIMS *m*/*z* 515.3708 \[M + Na\]^+^ (calcd. for C~30~H~52~O~5~Na, 515.3707).

3.4. Cytotoxicity Assay {#sec3dot4-marinedrugs-16-00093}
-----------------------

A549, DLD-1 and LNCap cancer cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Evaluation of cytotoxicity for the isolated metabolites from *L. michaelae* was performed according to the Alamar Blue assay \[[@B25-marinedrugs-16-00093],[@B26-marinedrugs-16-00093]\].

3.5. Human Neutrophil Superoxide Anion Generation and Elastase Release {#sec3dot5-marinedrugs-16-00093}
----------------------------------------------------------------------

Human neutrophils were isolated through dextran sedimentation and Ficoll centrifugation. By following the procedures described previously, the assay of superoxide anion generation was measured from the SOD-inhibitable reduction of ferricytochrome C. The elastase release experiment was performed according to methoxy-succinyl-alanyl-alanyl-prolyl-valine-*p*-nitroanilide (MeO-Suc-Ala-Ala-Pro-Val-*p*-nitroanilide) as the enzyme substrate. Results are expressed as the mean ± SEM, and comparisons were made using Student's *t*-test \[[@B27-marinedrugs-16-00093],[@B28-marinedrugs-16-00093]\].

4. Conclusions {#sec4-marinedrugs-16-00093}
==============

Our investigation demonstrated that a Taiwanese soft coral *L.* *michaelae* could be a good source of bioactive substances. Three new polyoxygenated steroids, michosterols A--C (**1**--**3**), were isolated. Compound **1** has an unusual side-chain, and **2** possesses a 17,20-double bound with rare substituents at both sp^2^ carbons. Compound **1** exhibited moderate anti-inflammatory activities in the inhibition of superoxide anion generation and elastase release in the fMLP/CB-stimulated human neutrophils, and **3** exhibited significant inhibitions toward elastase release, as well. Thus, compounds **1** and **3** can be considered as promising leads in the development of anti-inflammatory drugs.
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HRESIMS, ^1^H, ^13^C, HSQC, COSY, HMBC and NOESY NMR spectra of new compounds **1**--**3** are available online at <http://www.mdpi.com/1660-3397/16/3/93/s1>. Figure S1: HRESIMS spectrum of **1**, Figure S2: ^1^H NMR spectrum of **1** in CDCl~3~ at 400 MHz, Figure S3: ^13^C NMR spectrum of **1** in CDCl~3~ at 100 MHz, Figure S4: HSQC NMR spectrum of **1** in CDCl~3~ at 400 MHz, Figure S5: COSY NMR spectrum of **1** in CDCl~3~ at 400 MHz, Figure S6: HMBC NMR spectrum of **1** in CDCl~3~ at 400 MHz, Figure S7: NOESY NMR spectrum of **1** in CDCl~3~ at 400 MHz, Figure S8: HRESIMS spectrum of **2**, Figure S9: ^1^H NMR spectrum of **2** in CDCl~3~ at 500 MHz, Figure S10: ^13^C NMR spectrum of **2** in CDCl~3~ at 125 MHz, Figure S11: HSQC NMR spectrum of **2** in CDCl~3~ at 500 MHz, Figure S12: COSY NMR spectrum of **2** in CDCl~3~ at 500 MHz, Figure S13: HMBC NMR spectrum of **2** in CDCl~3~ at 500 MHz, Figure S14: NOESY NMR spectrum of **2** in CDCl~3~ at 500 MHz, Figure S15: HRESIMS spectrum of **3**, Figure S16: ^1^H NMR spectrum of **3** in CDCl~3~ at 400 MHz, Figure S17: ^13^C NMR spectrum of **3** in CDCl~3~ at 100 MHz, Figure S18: HSQC NMR spectrum of **3** in CDCl~3~ at 400 MHz, Figure S19: COSY NMR spectrum of **3** in CDCl~3~ at 400 MHz, Figure S20: HMBC NMR spectrum of **3** in CDCl~3~ at 400 MHz, Figure S21: NOESY NMR spectrum of **3** in CDCl~3~ at 400 MHz, Figure S22: ^1^H NMR spectrum of **3** in CD~3~OD at 400 MHz, Figure S23: ^13^C NMR spectrum of **3** in CD~3~OD at 100 MHz, Figure S24: HSQC NMR spectrum of **3** in CD~3~OD at 400 MHz, Figure S25: COSY NMR spectrum of **3** in CD~3~OD at 400 MHz, Figure S26: HMBC NMR spectrum of **3** in CD~3~OD at 400 MHz.
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Click here for additional data file.
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###### 

^13^C and ^1^H NMR data of compounds **1**--**3** in CDCl~3~.

  -----------------------------------------------------------------------------------------------------------------------------
           1             2                     3                                                          
  -------- ------------- --------------------- ------------- ------------------------------ ------------- ---------------------
  1        25.2, CH~2~   1.35 m; 1.81 m        25.1, CH~2~   1.33 m; 1.81 m                 25.1, CH~2~   1.34 m; 1.82 m

  2        27.7, CH~2~   1.59 m; 1.65 m        27.8, CH~2~   1.59 m                         27.6, CH~2~   1.59 m

  3        67.7, CH      4.27 br s             67.7, CH      4.25 br s                      66.9, CH      4.11 br s

  4        30.0, CH~2~   α: 1.93 m;\           29.9, CH~2~   1.81 m; 1.92 m                 31.1, CH~2~   1.92 br s
                         β: 1.87 m                                                                        

  5        78.1, C                             77.8, C                                      77.4, C       

  6        71.8, CH      3.82 dd (12.0, 4.8)   71.7, CH      3.80 dd (12.0, 5.0)            75.8, CH      4.97 dd (12.0, 4.8)

  7        34.5, CH~2~   α: 1.09 q (12.0)\     34.6, CH~2~   1.03 m;\                       33.6, CH~2~   1.07 m\
                         β: 1.85 m                           1.88 m                                       1.81 m

  8        32.4, CH      1.76 m                33.0, CH      1.63 m                         33.6, CH      1.56 m

  9        43.3, CH      1.34 m                42.9, CH      1.27 m                         42.7, CH      1.25 m

  10       41.1, C                             40.9, C                                      41.6, C       

  11       21.5, CH~2~   1.36 m; 1.51 m        22.0, CH~2~   1.38 m; 1.52 m                 21.4, CH~2~   1.29 m; 1.42 m

  12       35.8, CH~2~   α: 2.06 m;\           38.7, CH~2~   1.44 m;\                       39.7, CH~2~   1.13 m;\
                         β: 1.66 m                           2.27 m                                       1.99 br d (12.8)

  13       47.4, C                             44.1, C                                      42.6, C       

  14       57.8, CH      1.52 m                51.7, CH      1.09 m                         56.2, CH      1.07 m

  15       31.0, CH~2~   1.90 m; 2.12 m        29.4, CH~2~   1.69 m; 2.08 m                 24.0, CH~2~   1.05 m; 1.53 m

  16       127.0, CH     5.70 d (2.0)          86.1, CH      4.96 dd (7.5, 7.5)             28.0, CH~2~   1.28 m; 1.84 m

  17       157.6, C                            143.6, C                                     55.8, CH      1.13 m

  18       17.9, CH~3~   0.96 s                17.7, CH~3~   0.99 s                         11.9, CH~3~   0.64 s

  19       17.2, CH~3~   0.96 s                17.0, CH~3~   0.94 s                         17.0, CH~3~   0.97 s

  20       85.6, C                             132.8, C                                     36.2, CH      1.36 m

  21       22.4, CH~3~   1.31 s                19.4, CH~3~   1.71 s                         18.9, CH~3~   0.92 d (6.4)

  22       44.5, CH~2~   α: 1.99 m\            41.2, CH~2~   1.76 m; 2.43 dd (10.0, 13.5)   34.8, CH~2~   0.92 m; 1.50 m
                         β: 1.42 m                                                                        

  23       26.3, CH      2.05 m                29.6, CH      2.10 m                         27.8, CH~2~   0.77 m; 1.68 m

  24       46.1, CH      2.28 m                40.7, CH      2.24 m                         45.1, CH      1.27 m

  25       87.2, C                             87.0, C                                      73.6, C       

  26       24.1, CH~3~   1.41 s                24.0, CH~3~   1.41 s                         26.0, CH~3~   1.14 s

  27       25.8, CH~3~   1.50 s                25.3, CH~3~   1.43 s                         27.2, CH~3~   1.15 s

  28       9.3, CH~3~    0.88 d (7.2)          9.3, CH~3~    0.81 d (7.0)                   14.8, CH~3~   0.88 d (6.8)

  29       18.0, CH~3~   0.93 d (6.8)          16.7, CH~3~   0.86 d (7.0)                                 

  OAc      22.7, CH~3~   2.03 s                22.7, CH~3~   2.00 s                         21.3, CH~3~   2.03 s

           171.9, C                            171.2, C                                     171.9, C      

  6-OH                   4.11 br s                           4.01 br s                                    

  20-OOH                 8.06 br s                           8.91 br s                                    
  -----------------------------------------------------------------------------------------------------------------------------

*^a^* Spectrum recorded at 100 MHz; *^b^* attached protons were deduced by the DEPT experiment; *^c^* spectrum recorded at 400 MHz; *^d^* *J* values (in Hz) in parentheses; *^e^* spectrum recorded at 125 MHz; *^f^* spectrum recorded at 500 MHz.
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###### 

The ^1^H NMR chemical shifts and coupling constants of the H-3 and H-6 of compound **1** and the related steroids \[[@B22-marinedrugs-16-00093]\].

  --------------------------------------------------------------------------------------------------------------------------------------------------
        Michosterol A (1)    5α-Cholestane-3β,5,6α-Triol   5α-Cholestane-3β,5,6β-Triol   5β-Cholestane-3β,5,6α-Triol   5β-Cholestane-3β,5,6β-Triol
  ----- -------------------- ----------------------------- ----------------------------- ----------------------------- -----------------------------
  H-3   4.27, br s           4.06, m                       4.09, m                       4.24, s                       4.14, s

  H-6   3.82, dd,\           3.64, dd                      3.53, s                       3.74--3.81, dd,\              3.56, m
        *J* = 12.0, 4.8 Hz                                                               *J* = 12.0, 4.8 Hz            
  --------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Inhibitory effects of compounds **1**--**3** on superoxide anion generation and elastase release in *N*-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLP/CB)-induced human neutrophils at 10 μM.

  Compound     Superoxide Anion Generation                 Elastase Release                            
  ------------ ----------------------------- ------------- ------------------ ----------- ------------ --------
  1            7.1 ± 0.3                     63.1 ± 1.1    \*\*\*             4.5 ± 0.9   91.7 ± 3.1   \*\*\*
  2            \>10                          14.7 ± 5.7                       \>10        31.8 ± 5.0   \*\*
  3            \>10                          17.8 ± 2.8    \*\*               0.9 ± 0.1   95.4 ± 3.6   \*\*\*
  Idelalisib   0.07 ± 0.01                   102.8 ± 2.2   \*\*\*             0.3 ± 0.1   99.6 ± 4.2   \*\*\*

***^a^*** Concentration necessary for 50% inhibition (IC~50~); *^b^* percentage of inhibition (Inh%) at a 10 μM concentration. Results are presented as the mean ± S.E.M. (*n* = 3--4). \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 compared with the control value.
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